Amydis
Amydis is a leader in developing a new class of ocular tracers that enable digital detection and monitoring of human disease-related molecular biomarkers through standard ocular imaging cameras. This pioneering technology can accelerate diagnosis, improve the clinical testing of novel therapeutics, and revolutionize treatment. The company leverages the eye as a 'window to the body' for early, non-invasive detection of diseases affecting the eye, heart, and brain. Their proprietary ocular tracers identify molecular biomarkers for these conditions, creating a data warehouse for multi-omics and AI-enabled health insights. Amydis aims to empower eye care providers to detect neurodegenerative and cardiological diseases at early stages, potentially before symptoms arise, thereby facilitating precision treatment and improving patient outcomes. The company is currently in human clinical trials.
Amydis
Amydis is a leader in developing a new class of ocular tracers that enable digital detection and monitoring of human disease-related molecular biomarkers through standard ocular imaging cameras. This pioneering technology can accelerate diagnosis, improve the clinical testing of novel therapeutics, and revolutionize treatment. The company leverages the eye as a 'window to the body' for early, non-invasive detection of diseases affecting the eye, heart, and brain. Their proprietary ocular tracers identify molecular biomarkers for these conditions, creating a data warehouse for multi-omics and AI-enabled health insights. Amydis aims to empower eye care providers to detect neurodegenerative and cardiological diseases at early stages, potentially before symptoms arise, thereby facilitating precision treatment and improving patient outcomes. The company is currently in human clinical trials.